Nitrogenated bicyclic aromatic heterocyclic compound

The present invention provides an excellent therapeutic or prophylactic agent for autoimmune diseases, allergic diseases, graft rejection in an organ, the bone marrow or a tissue, systemic lupus erythematosus or the like, which relies on a cathepsin-S-inhibiting activity. It is confirmed that a nitr...

Full description

Saved in:
Bibliographic Details
Main Authors SATO JUNJI, AOYAMA NAOHIRO, NAKAJIMA YUTAKA, IMADA SUNAO, NAKANISHI KEITA, NIGAWARA TAKAHIRO, SHIRAI FUMIYUKI, SHIRAKAMI SHOHEI, KUBO KAORI, TAKASUNA YUJI
Format Patent
LanguageEnglish
Published 14.01.2015
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides an excellent therapeutic or prophylactic agent for autoimmune diseases, allergic diseases, graft rejection in an organ, the bone marrow or a tissue, systemic lupus erythematosus or the like, which relies on a cathepsin-S-inhibiting activity. It is confirmed that a nitrogenated bicyclic heterocyclic compound represented by formula (I) has a good cathepsin-S-inhibiting activity, and this confirmation leads to the accomplishment of the present invention. The compound according to the present invention has a cathepsin-S-inhibiting activity and therefore can be used as a therapeutic and/or prophylactic agent for autoimmune diseases, allergic diseases, graft rejection in an organ, the bone marrow or a tissue, systemic lupus erythematosus or the like.
Bibliography:Application Number: CN201380020404